+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
VENMAX VENMAX

Venmax Drugs & Pharmaceuticals Share Price

₹14.85 +1.25 (9.19%)
New 52W Low in past week

18 Sep, 2026 4:01 PM (IST)

Venmax Drugs & Pharmaceuticals live price: ₹14.85. It opened at ₹15 vs previous close ₹14; intraday high/low: ₹15/₹14. The 50 & 200 DMA stand at ₹16.40/₹20.80.

Venmax Drugs & Pharmaceuticals Performance

  • Today's Low
  • ₹14
  • Today's High
  • ₹15
  • 52 Week Low
  • ₹13
  • 52 Week High
  • ₹32
  • Open Price₹15
  • Previous Close₹14
  • Volume26,101
  • 50 DMA₹16.40
  • 100 DMA₹18.50
  • 200 DMA₹20.80

Venmax Drugs & Pharmaceuticals Chart

Investment Returns

  • Over 1 Month -11.24%
  • Over 3 Month -25.26%
  • Over 6 Month -39.14%
  • Over 1 Year -41.19%

Smart Investing Starts Here Start SIP with Venmax Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Venmax Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 46.5
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 13
  • P/B Ratio
  • 1.1
  • Average True Range
  • 1.9
  • EPS
  • 0.3
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.6
  • RSI
  • 46.62
  • MFI
  • 54.86

Latest Stock News Updates

Venmax Drugs and Pharmaceuticals Ltd - 531015 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement

Venmax Drugs and Pharmaceuticals Limited has informed the exchange about the update in respect of Scheme of Amalgamation of Hatri Pharma Private Limited (Amalgamating Company) with Venmax Drugs and Pharmaceuticals Limited ( Amalgamated Company).

Venmax Drugs and Pharmaceuticals Ltd - 531015 - Reg. 34 (1) Annual Report.

Submission of Annual Report for the Financial Year 2025-26 Pursuant to Regulation 34 and other relevant provisions of the SEBI (Listing Obligations & Disclosure Requirements), 2015.

Venmax Drugs and Pharmaceuticals Ltd - 531015 - Board Meeting Outcome for Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, we would like to inform you that a meeting of Board of Directors of was held today i.e August 31, 2026 at the registered office of the Company.

Venmax Drugs & Pharmaceuticals Financials

Venmax Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹14.85
+ 1.25 (9.19%)
pointer
  • Bearish Moving Average 11
  • Bullish Moving Average 5
  • 20 Day
  • ₹15.10
  • 50 Day
  • ₹16.40
  • 100 Day
  • ₹18.50
  • 200 Day
  • ₹20.80

Resistance and Support

14.48 Pivot Speed
  • R3 16.40
  • R2 15.70
  • R1 15.20
  • S1 14.00
  • S2 13.30
  • S3 12.80

Venmax Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-31 A.G.M.
2026-08-07 Quarterly Results
2026-05-14 Audited Results
2026-02-07 Quarterly Results
2025-11-12 Quarterly Results

Venmax Drugs & Pharmaceuticals Shareholding Pattern

89.53%
10.46%
0%

About Venmax Drugs & Pharmaceuticals

Venmax Drugs & Pharmaceuticals is engaged in the business of pharmaceutical products, drug intermediaries and API’s View More
  • NSE Symbol
  • VENMAX
  • BSE Symbol
  • 531015
  • ISIN
  • INE154G01022

Similar Stocks to Venmax Drugs & Pharmaceuticals

Venmax Drugs & Pharmaceuticals FAQs

Venmax Drugs & Pharmaceuticals share price is ₹14 As on 19 September, 2026 | 16:15

The Market Cap of Venmax Drugs & Pharmaceuticals is ₹13 Cr As on 19 September, 2026 | 16:15

The P/E ratio of Venmax Drugs & Pharmaceuticals is 46.5 As on 19 September, 2026 | 16:15

The PB ratio of Venmax Drugs & Pharmaceuticals is 1.1 As on 19 September, 2026 | 16:15

The 52 week High & Low of Venmax Drugs & Pharmaceuticals is ₹31.5/₹12.7 respectively As on 19 September, 2026 | 16:15

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23